Group 1 - The core point of the article is that Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Linggui Zhugan Decoction Granules, which is expected to positively impact the company's performance [1][2]. - The drug is classified as a traditional Chinese medicine (Category 3.1) and is intended for the treatment of symptoms related to insufficient middle yang and phlegm-dampness [1][2]. - The company has invested approximately 12.7 million RMB in the research and development of this drug [2]. Group 2 - As of the announcement date, there are four approved drug registration numbers for Linggui Zhugan Decoction Granules, with the company being the fourth to receive approval [2]. - The market for cardiovascular disease medications, including traditional Chinese medicine, reached a total sales amount of 50.431 billion RMB in 2024, showing a year-on-year decline of 3.10% [2]. - The sales amount for Linggui Zhugan Decoction Granules in 2024 was reported to be 210,000 RMB, following its market entry in December 2022 [2].